• COVID-19/SARS/influenza/EV/dengue cases

• Airport/quarantine hotel screening

• Vaccine/antiviral trial participants

• Domestic vaccine validation

• CDC LIMS cases

• Latin American & Caribbean medical students

Linkou CGMH Department of Laboratory Medicine was the first in Taiwan to obtain CAP accreditation (2003) and received the National Biotech Medical Quality Gold Award (Hospital Specialty Group) in 2004. Established in 1999, the Virus Detection Center integrates BSL-2 and BSL-3 labs with Taiwan's most comprehensive cell/virus library (>100 strains), 43 molecular tests (identifying 200+ viral genotypes), 10 antigen tests, and 35 antibody tests. SARS-CoV-2 PCR launched 2020/1/21—the first batch lab; total tests 307,327, including airport surveillance (peak 2,026/day, 100% 24-hour turnaround). Three high-throughput platforms (Cobas 6800/8800, Alinity m—Taiwan's first) enable 5,800 tests/day. Innovations: (1) in-house AI sample-recognition system (150,000 system-wide electronic verifications/month); (2) whole-genome sequencing tracking viral evolution, 90 entries uploaded to GISAID; (3) real-time S-protein variant sequencing; (4) validated 5 manufacturers' PCR kits; led MVC vaccine Phase I/II trials (Lancet Respir Med IF 30.7); (5) world-first quantitative neutralizing antibody ELISA technology-transferred. COVID-19 culture positive rate 62.5%—world #1. Published 304 viral papers; remote training for 40 students from 9 Latin American/Caribbean allies.

• Taiwan's first CAP-accredited lab (2003)

• In-house AI sample-recognition system

• Whole-genome sequencing for viral evolution

• World-first quantitative neutralizing Ab ELISA tech-transfer

• Taiwan's first Alinity m platform

• BSL-3 culturing of SARS-CoV-1/2 and H7N9

• 307,327 SARS-CoV-2 PCR tests

• 5,800 PCR tests/day capacity

• Peak 2,026 airport tests/day

• 100% 24-hour turnaround

• 90 whole-genome sequences

• Uploaded to GISAID platform

• COVID-19 culture positive 62.5% (world #1)

• 189,930 epidemic reports (TW #1)

• Higher than South Korea 18%, HK 24%, USA 58%

• 5 PCR kit validations

• Distributed virus to TFDA (3), NDMC (2)

• Multiple IF>5 papers

• AI real-time abnormal sample interception

• 150,000 monthly e-verifications

• Two-way connectivity for report accuracy

• Customized sample storage positioning

• Barcode-based rapid retrieval

• CAP accreditation ensures quality

• Clinicians praise turnaround time

• 24/7 full-platform service

• Coordinates with govt missions

• Quality system shared across branches

• National pandemic achievements

• Continuous improvement in clinical relations

• 304 viral research papers

• 162 as first/corresponding author

• 56 high-impact papers

• Lancet Respir Med (IF 30.7) MVC vaccine

• Emerg Microbes Infect (IF 5.84)

• MOST Tech Transfer Award; Taipei City Invention Award

• WHO online conference tech sharing (5,000 attendees)

• Remote teaching for 40 students from 9 allies

• Virus sharing with U-Washington

• Cooperated with US CDC on first EV71 autopsy

• Linked with CGU New Emerging Virus Center, John Hopkins

• Drives Taiwan biotech-diagnostics industry